| [1] |
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-86 doi: 10.1002/ijc.29210
|
| [2] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-32 doi: 10.3322/caac.21338
|
| [3] |
Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database[J]. J Clin Oncol, 2006, 24(28): 4539-44 doi: 10.1200/JCO.2005.04.4859
|
| [4] |
Abajobir AA, Abbafati C, Abbas KM, et al. Global, regional, and National age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the global burden of disease study 2016[J]. Lancet, 2017, 390(10100): 1151-210 doi: 10.1016/S0140-6736(17)32152-9
|
| [5] |
Nicholson AG, Chansky K, Crowley J, et al. The international association for the study of lung cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer[J]. J Thorac Oncol, 2016, 11(3): 300-11 doi: 10.1016/j.jtho.2015.10.008
|
| [6] |
Fitzmaurice C, Collaboration GB, Allen C, et al. Global, regional, and National cancer incidence, mortality, years of Life lost, years lived with disability, and Disability-Adjusted life-years for 32 cancer groups, 1990 to 2015 a systematic analysis for the global burden of disease study[J]. JAMA Oncol, 2017, 3(4): 524-48 doi: 10.1001/jamaoncol.2016.5688
|
| [7] |
George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer[J]. Nature, 2015, 524(7563): 47-53 doi: 10.1038/nature14664
|
| [8] |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108 doi: 10.3322/caac.21262
|
| [9] |
Silva M, Galeone C, Sverzellati N, et al. Screening with low-dose computed tomography does not improve survival of small cell lung cancer[J]. J Thorac Oncol, 2016, 11(2): 187-93 doi: 10.1016/j.jtho.2015.10.014
|
| [10] |
Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide[J]. N Engl J Med, 1999, 340(4): 265-71 doi: 10.1056/NEJM199901283400403
|
| [11] |
Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial[J]. Lancet Oncol, 2017, 18(8): 1116-25 doi: 10.1016/S1470-2045(17)30318-2
|
| [12] |
Jackman DM, Johnson BE. Small-cell lung cancer[J]. Lancet, 2005, 366(9494): 1385-96 doi: 10.1016/S0140-6736(05)67569-1
|
| [13] |
Rossi A, Di Maio M, Chiodini P, et al. Carboplatin-or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data[J]. J Clin Oncol, 2012, 30(14): 1692-8 doi: 10.1200/JCO.2011.40.4905
|
| [14] |
Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer[J]. N Engl J Med, 2002, 346(2): 85-91 doi: 10.1056/NEJMoa003034
|
| [15] |
von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as Second-Line treatment for patients with Small-Cell lung cancer[J]. J Clin Oncol, 2014, 32(35): U160-4012
|
| [16] |
Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial[J]. Lancet, 2015, 385(9962): 36-42 doi: 10.1016/S0140-6736(14)61085-0
|
| [17] |
Slotman BJ, van Tinteren H, Praag JO, et al. Radiotherapy for extensive stage small-cell lung cancer - Authors' reply[J]. Lancet, 2015, 385(9975): 1292-3
|
| [18] |
Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer[J]. N Engl J Med, 2007, 357(7): 664-72 doi: 10.1056/NEJMoa071780
|
| [19] |
Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2017, 18(5): 663-71 doi: 10.1016/S1470-2045(17)30230-9
|
| [20] |
Aizer AA, Mak R, Alexander BM. Prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer[J]. Neuro Oncol, 2017, 19(8): 1015-6 doi: 10.1093/neuonc/nox113
|
| [21] |
Slotman BJ. Time to reconsider prophylactic cranial irradiation in extensive-stage small-cell lung cancer[J]. Lancet Oncol, 2017, 18(5): 566-7 doi: 10.1016/S1470-2045(17)30193-6
|
| [22] |
Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1[J]. Cancer Discov, 2012, 2(9): 798-811 doi: 10.1158/2159-8290.CD-12-0112
|
| [23] |
de Bono J, Ramanathan RK, Mina L, et al. Phase I, Dose-Escalation, Two-Part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers[J]. Cancer Discov, 2017, 7(6): 620-9 doi: 10.1158/2159-8290.CD-16-1250
|
| [24] |
Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in Life[J]. Nature, 2011, 469(7330): 343-9 doi: 10.1038/nature09784
|
| [25] |
Gardner EE, Lok BH, Schneeberger VE, et al. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis[J]. Cancer Cell, 2017, 31(2): 286-99 doi: 10.1016/j.ccell.2017.01.006
|
| [26] |
Leijen S, van Geel RM, Pavlick AC, et al. Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors[J]. J Clin Oncol, 2016, 34(36): 4371-80 doi: 10.1200/JCO.2016.67.5991
|
| [27] |
Do K, Wilsker D, Ji J, et al. Phase I study of Single-Agent AZD1775 (MK-1775), a wee1 kinase inhibitor, in patients with refractory solid tumors[J]. J Clin Oncol, 2015, 33(30): 3409-15 doi: 10.1200/JCO.2014.60.4009
|
| [28] |
Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo[J]. Sci Transl Med, 2015, 7(32): 302-6
|
| [29] |
Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study[J]. Lancet Oncol, 2017, 18(1): 42-51 doi: 10.1016/S1470-2045(16)30565-4
|
| [30] |
Lu Y, Liu Y, Jiang J, et al. Knocking down the expression of Aurora-A gene inhibits cell proliferation and induces G2/M phase arrest in human small cell lung cancer cells[J]. Oncol Rep, 2014, 32(1): 243-9 doi: 10.3892/or.2014.3194
|
| [31] |
Mollaoglu G, Guthrie MR, Böhm S, et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition[J]. Cancer Cell, 2017, 31(2): 270-85 doi: 10.1016/j.ccell.2016.12.005
|
| [32] |
Melichar B, Adenis A, Lockhart AC, et al. Safety and activity of alisertib, an investigational Aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study[J]. Lancet Oncol, 2015, 16(4): 395-405 doi: 10.1016/S1470-2045(15)70051-3
|
| [33] |
Zarogoulidis K, Ziogas E, Boutsikou E, et al. Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study[J]. Drug Des Devel Ther, 2013, 7(2): 611-7
|
| [34] |
Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 Cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer[J]. Clin Cancer Res, 2006, 12(3 Pt 1): 878-87
|
| [35] |
Krug LM, Ragupathi G, Hood C, et al. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin[J]. Clin Cancer Res, 2004, 10(18 Pt 1): 6094-100
|
| [36] |
Giaccone G, Debruyne C, Felip E, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer[J]. J Clin Oncol, 2005, 23(28): 6854-64 doi: 10.1200/JCO.2005.17.186
|
| [37] |
Wei SC, Levine JH, Cogdill AP, et al. Distinct cellular mechanisms underlie Anti-CTLA-4 and Anti-PD-1 checkpoint blockade[J]. Cell, 2017, 170(6): 1120-33 doi: 10.1016/j.cell.2017.07.024
|
| [38] |
Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial[J]. Ann Oncol, 2013, 24(1): 75-83 doi: 10.1093/annonc/mds213
|
| [39] |
Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and Platinum versus placebo plus etoposide and Platinum in Extensive-Stage Small-Cell lung cancer[J]. J Clin Oncol, 2016, 34(31): 3740-8 doi: 10.1200/JCO.2016.67.6601
|
| [40] |
Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial[J]. Lancet Oncol, 2016, 17(7): 883-95 doi: 10.1016/S1470-2045(16)30098-5
|
| [41] |
Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with Extensive-Stage Small-Cell lung cancer: results from the phase Ib KEYNOTE-028 study[J]. J Clin Oncol, 2017, 35(34): 3823-9 doi: 10.1200/JCO.2017.72.5069
|
点击查看大图
下载:
